Xtrackers MSCI EAFE Hedged Equity ETF
DBEF - ETF AI Analysis
Top Page
Xtrackers MSCI EAFE Hedged Equity ETF (DBEF)
DBEF’s rating suggests it is a solid, but not top-tier, international equity ETF, helped by strong core holdings like HSBC, Novartis, and AstraZeneca, which show healthy financial performance and positive outlooks. These strengths are balanced by more mixed names such as SAP and Shell, where weaker technical trends, growth challenges, or valuation concerns limit their contribution. The main risk is that many top holdings are large non-U.S. financials and healthcare companies, so the fund is exposed to sector and regional developments in those areas.
DBEF vs. SPDR S&P 500 ETF (SPY)
- AUM
- 9.55B
- Region
- Developed Markets
- Expense Ratio
- 0.35%
- Beta
- 0.71
- Issuer
- Xtrackers
- Inception Date
- Jun 09, 2011
- Dividend Yield
- 4.76%
- Asset Class
- Equity
- Index Tracked
- MSCI EAFE 100% Hedged to USD Net Variant
DBEF Summary
DBEF is an ETF that tracks the MSCI EAFE index, which covers large and mid-sized companies in developed markets outside the U.S. and Canada, such as Japan, the UK, and Europe. It owns many well-known international names like Nestlé and AstraZeneca, and it spreads your money across many sectors, helping with global diversification. A key feature is that it hedges currencies, aiming to reduce the impact of foreign exchange swings so you mainly follow stock performance. A simple risk to remember is that international stocks can still go up and down with global markets.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s a bit higher than the cheapest index ETFs because this fund adds a currency-hedging strategy on top of its passive index tracking, which increases costs slightly.
What would affect this ETF?
DBEF could benefit if developed markets in Europe and Asia grow steadily, especially in sectors like financials, industrials, and health care, and if its major holdings such as ASML, Roche, and HSBC perform well, while its currency hedging helps reduce the impact of a strong or volatile U.S. dollar. On the downside, slower global economic growth, banking or energy sector stress, or unfavorable regulations in key countries could hurt these international stocks, and the fund may lag unhedged peers if foreign currencies strengthen significantly against the dollar.
DBEF Top 10 Holdings
DBEF is leaning on a mix of European heavyweights, with ASML and SAP giving the fund a tech edge as both have been rising over the past few months, even if ASML has cooled a bit lately. Health care names like Roche and Novartis are steady engines, adding defensive strength with generally solid, upward trends. On the flip side, consumer giant Nestlé and pharma player AstraZeneca have been more mixed, occasionally losing steam and holding back returns. Overall, the ETF is diversified across sectors and focused on developed markets outside North America, with a clear tilt toward European blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.63% | $245.91M | EUR 511.40B | 51.88% | 76Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| HSBC Holdings | 1.41% | $132.04M | GBP 231.98B | 20.93% | 80Outperform | |
| Novartis AG | 1.34% | $125.48M | CHF 245.40B | 26.78% | 80Outperform | |
| Shell (UK) | 1.31% | $122.35M | GBP 210.62B | 30.08% | 73Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Nestlé SA | 1.23% | $115.47M | CHF 225.64B | 8.18% | 71Outperform | |
| SAP SE | 1.10% | $102.42M | EUR 249.22B | -2.13% | 66Neutral | |
| Mitsubishi UFJ Financial Group | 1.07% | $99.82M | JPY 39.11T | 41.84% | 76Outperform | |
| Siemens | 1.02% | $95.65M | EUR 212.98B | 23.08% | 74Outperform |
DBEF Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DBEF, the sentiment is Positive. The current price of 56.04 is above the 20-day moving average (MA) of 55.03, above the 50-day MA of 55.03, and above the 200-day MA of 53.28, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 58.28 is Neutral, neither overbought nor oversold. The STOCH value of 95.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBEF.
DBEF Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $56.04 | $60.00(7.07% Upside) | $9.55B | 0.35% | 65Neutral | |
| $78.10 | $91.95(17.73% Upside) | $6.54B | 0.07% | 66Neutral | |
| $96.91 | $101.95(5.20% Upside) | $5.65B | 0.20% | 61Neutral | |
| $36.61 | $45.19(23.44% Upside) | $2.55B | 0.20% | 60Neutral | |
| $53.10 | $62.85(18.35% Upside) | $2.11B | 0.58% | 66Neutral | |
| $46.50 | $52.60(13.13% Upside) | $1.45B | 0.40% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DBEF | Xtrackers MSCI EAFE Hedged Equity ETF | 56.04 | 9.47 | 20.33% | |
| BBIN | JPMorgan BetaBuilders International Equity ETF | 78.10 | 9.98 | 14.66% | |
| EFAV | iShares MSCI EAFE Min Vol Factor ETF | 96.91 | 14.12 | 17.05% | |
| HFXI | IQ 50 Percent Hedged FTSE International ETF | 36.61 | 5.84 | 18.98% | |
| IHDG | WisdomTree International Hedged Quality Dividend Growth Fund | 53.10 | 7.05 | 15.30% | |
| DDWM | WisdomTree Dynamic Currency Hedged International Equity Fund | 46.50 | 5.52 | 13.48% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
